Franklin Resources
RNAC icon

Franklin Resources’s Cartesian Therapeutics RNAC Stock Holding History

Franklin Resources’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,031
Closed -$68.8K – 2379
2022
Q4 		$68.8K Hold
2,031
– – ﹤0.01% 2177
2022
Q3 		$100K Hold
2,031
– – ﹤0.01% 2103
2022
Q2 		$80K Sell
2,031
-983
-33% -$29.1K ﹤0.01% 2181
2022
Q1 		$111K Hold
3,014
– – ﹤0.01% 2279
2021
Q4 		$295K Sell
3,014
-9
-0.3% -$968 ﹤0.01% 2088
2021
Q3 		$377K Buy
+3,023
New +$365K ﹤0.01% 1996

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Franklin Resources's RNAC Position: Q1 2023 in Review

Franklin Resources sold out of Cartesian Therapeutics (RNAC) in Q1 2023, closing a stake of 2,031 shares — an estimated $68.8K sold.

Franklin Resources first reported a position in RNAC in Q3 2021 and held it in 6 quarters. The position peaked at $377K in Q3 2021. 93 funds tracked by Wall St. Rank hold RNAC as of Q1 2023.

  • Franklin Resources reported no remaining Cartesian Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Franklin Resources sold 2,031 Cartesian Therapeutics shares in Q1 2023, an estimated $68.8K.
  • Franklin Resources first reported a position in Cartesian Therapeutics in Q3 2021 and held it in 6 quarters.
  • Franklin Resources's Cartesian Therapeutics position peaked at $377K in Q3 2021.
  • 93 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2023.

Based on Franklin Resources's 13F filing for Q1 2023, filed 12 May 2023.